Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We'll see. India is giving QMC the opportunity to produce end product.
MILESTONES – Licensor
a) Licensor is obligated to continual to improve and optimize their patented quantum dot solar cell technology and to achieve a peak solar cell conversion efficiency of 15% on or before the 18th month following execution of this agreement. If licensor does not achieve this target performance within this time frame the licensee will deduct and accrue 10% from the total amount of royalties owing until such time the target performance is achieved. Once the target is achieved the accrued royalties will be paid to licensor.
b) Licensor is obligated to timely ship production and process equipment and to insure all equipment is of the latest generation. Licensor will make all shipments expeditiously and any shipments that are delayed beyond the initial target date and effect the licensee milestone dates will automatically add 15 days to the licensee milestone dates referenced above.
Share Price is 2.30 Divided by 2 == 1.15 a share before losing $$$. Pretty safe buy. IMO
Good Rebound Today.
Im sure Jabbour and Squires have been twitling their thumbs on this for the last 10 years and India took a blind eye in this. Have you visited San Marcos. ?
Charade-We'll see once India starts Manufacturing PQD Solar.
Dividend in stone Oct 31, NASDAQ Probably however not certain however probable.
Yes it is easy to understand. Nothing wrong with rewarding shareholders. Buy 1000 get an extra 1000 in October. The additional shares are pretty much dilution free per prior PR's.
We will know much more in the next 3-6 Months in India.
India is Progressing, Its not time to get out the pitchforks. BTW that Press Release confirmed 2 Reactors we're sent to India. People are selling because there impatient.
Lets see how India pans b4 passing judgement. Your comments are welcome and understandable although I believe that Amtronics is for real and making progress however slower than some here would like.
License & Development Signed & 2 Reactors shipped. QMC's future has improved immensely.
Correction A PR will be issued.
Maybe a person who has been around longer than myself can explain this. I bought in before July 24th.
Hey Mike, the 1:1 Dividend is coming to shareholders who bought before July 24th. I bought in before that date and will get double the shares when they land on the NASDAQ for shareholders not management, giving up and retiring shares adding little to dilution. Not sure if the date was extended however stated if shares are bought from other shareholders before NASDAQ they would be transferred over.
BBaller is right that they did a R/S several months ago and have acquired other health and bio companies and clinical trials. Yes they also have Notes which they are cleaning up. they have about 60M and cleaning up Notes which may be the recent volatility.
Generex is cleaning up its Balance Sheet. CEO Joe has done a great job preparing this company to enter the NASDAQ.
Thank you for the shoutout doc. I see a company with quite a potential as I learn more about it. They not only can grow organically thru expansion, they also can get approval thru clinical trials on a number of life saving treatments including one with Merck. I am impressed as I learn more about what Generex has to offer.
Generex News Alert:
Generex to Announce Positive Shareholder News on
Monday August 12, 2019 at 8 AM
Payment Details for the 1:1 GNBT Stock Dividend
-
Dividend to be Paid to show Appreciation to our Shareholders
MIRAMARFL, August 9, 2019/
--
Generex
Biotechnology
Corporation
(www.generex.com) (OTCQB:GNBT) (“Generex”) today provided a news alert for GNBT
shareholders that the Company will make an announcement on Monday August 12, 2019
at 8 AM pertaining to the payment of the previously announced 1:1 stock dividend.
Joseph Moscato, Generex President & Chief Executive Officer stated, “Generex plans to
announce significant and positive information for investors on Monday after we finalize
details regarding the shareholder dividend, which is being paid to reward Generex’s loyal
shareholders for their support as we execute on our strategic plan to build a new model
for healthcare.”
Generex will publish a press release on Monday August 12, 2019 at 8 AM with full details.
Joseph Moscato - Chief Executive Officer, President and Chairman of the Board
Mr. Moscato has over 30 years of experience in healthcare, sales and marketing, distribution management, and finance. Mr. Moscato brings his marketing and advertising acumen to drug discovery and diagnostic & treatment development and commercialization. Since 2009, Mr. Moscato has been working as an exclusive consultant to the Company. Mr. Moscato has originated and negotiated several licensing deals with the top biopharmaceutical companies; has advised on equity financings totaling over $300 million, and has implemented the broad strategic vision for the Company. Mr. Moscato has worked and consulted for Pfizer in several capacities from sales and marketing to new drug discovery & development for licensing. He has worked with other biopharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson, Parke-Davis, Amgen and others. Mr. Moscato has consulted for several healthcare focused private equity, hedge funds and family offices.
Mr. Moscato also owned several advertising and marketing agencies focused on media, entertainment, and healthcare with clients ranging from Motorola, Chadmoore Wireless, Nextel, Cannon, Sharp, GlaxoSmithKline, Pfizer, and other biopharmaceutical companies. Mr. Moscato’s agency was acquired by William Douglas McAdams, one of the largest independent healthcare advertising and marketing agencies.
Terry Thompson - Chief Operating Officer
Terry Thompson brings a wealth of experience and expertise in healthcare, providing executive leadership in pharmacy benefits management, network administration, claims processing, and distribution & logistics for drugs, durable medical equipment (DME), and infusion therapy, as illustrated by his impressive 35-year career.
Mr. Thompson started his career working with FedEx, one of the most successful startups of our era, from the company’s pre-IPO infancy to its proven “changing the way the world does business” outcome. After leaving FedEx, he used his expertise in healthcare, focusing on the pharmacy sector, to participate in the creation of the nation’s first Pharmacy Benefits Manager (PBM), Medco Containment Services, ultimately serving as Executive Vice President of Merck-Medco post-acquisition, and President of National Rx Services and Paid Prescriptions. Following his work with Medco, Mr. Thompson was COO of Synetic, Inc.’s Institutional Pharmacies, where he assimilated numerous acquired full service companies. Additionally, he brings relevant experience as Chief Operating Officer of Merit Behavioral Care Corp., a KKR buyout and largest Specialty HMO at the time, Chief Executive Officer of Closer HealthCare, Inc., a DME and Diabetic Supply Company, supporting the NIH’s ACCORD and BARI IID clinical trials, and Independent Director of ProVantage Health, a billion dollar publicly traded PBM. For the last several years, Mr. Thompson has provided consulting services to C-Level executives and their teams, primarily in healthcare.
Andrew Ro - Chief Investment Officer and a Director
Mr. Ro has over 20 years’ experience in the financial markets ranging from trading global futures and equity markets, senior secured debt, convertible securities, private investments in public equities (PIPEs) and investing. Mr. Ro was a Consultant and Registered Representative with boutique investment and merchant banks where he consulted and advised US and international companies on capital markets, operational, and regulatory issues as well as being involved in capital raising, mergers & acquisitions, and strategic implementation. Mr. Ro was a Partner with an active Investment Fund where he was involved in originating, structuring, negotiating and closing financing transactions providing growth capital, acquisition financing, recapitalization, restructuring and general working capital to late-stage venture, distressed and middle market companies across all industries and sectors. Mr. Ro originated and structured over $2 billion in total commitments and managed a portfolio of over $650 million in investments. Mr. Ro graduated from George Mason University with a Bachelor in Science in Economics. He also held Series 3, Series 7, and Series 63 licenses.
Mark Corrao - Chief Financial Officer and Treasurer
Mr. Corrao has experience in financial management with a proven track record of raising capital and extraordinary bottom line management. He has been involved in the initial registration of numerous public companies and subsequent SEC quarterly and annual reporting and has developed, authored and presented numerous business plans and models inclusive of budgets, forecasts, cash flow, cash management and investment strategies. From 2012 to present he has been a Managing Director and CFO of The Mariner Group LLC, which has merged with the CFO Squad, creating a much larger and diverse multi-talented organization. The CFO Squad is a financial and business advisory firm providing outsourced and part-time CFO services for emerging to midsized companies (both private and public) in a wide range of businesses and industries. He is the Chief Financial Officer for a pharmaceutical company specializing in the research and development of novel and new therapeutic agents designed to reduce oxidative stress and act as immune modulators and Neuroprotectants. From 2010-12, he served as Chief Financial Officer of New York Business Efficiency Experts, Inc. which provides professional services in the financial areas of accounting, taxation, auditing, venture capital and SEC registrations (reporting). He served as a Director and Chief Financial Officer for a manufacturer of proprietary software for the prevention of identity theft and the protection of computer systems from unauthorized access. Additionally, Mr. Corrao is currently the CFO for a software company.
Dr. Jason B. Terrell, MD. - Chief Scientific Officer and Chief Medical Officer
Dr. Terrell has extensive expertise in the pharmaceutical and medical diagnostic device industry in the areas of business development, clinical trial organization, regulatory affairs and commercialization strategies. Dr. Terrell has served as medical director and chief medical officer for several public and private companies like VolitionRx, a NYSE traded international medical diagnostic company. Dr. Terrell previously served as a Corporate Medical Director for Any Lab Test Now, the nation’s largest direct to consumer medical testing franchise, where he supervised clinical operations for over 70 locations throughout the United States. Dr. Terrell is a summa cum laude graduate from Hardin-Simmons University with a degree in Biochemistry. He graduated as recipient of the Holland Medal of Honor for the top graduate in the School of Science and Mathematics. Dr. Terrell was honored with the Hardin-Simmons University Outstanding Young Alumni Award and currently serves on the University’s Board of Development. Dr. Terrell is an Assistant Clinical Professor of Oncology at the University of Texas Dell Medical School in Austin, Texas, he attended The University of Texas School of Medicine in Houston and received General Medicine Internship and Pathology Residency training at the Texas Tech University Health Sciences Center.
Richard Purcell - Senior Vice-President of Research & Drug Development
Mr. Purcell has over 30 years of experience in consulting and advising emerging biopharmaceutical and technology companies on new business strategy, operations management, clinical development of novel compounds, data solutions for clinical and medical applications, patient engagement & communication, medical education for professionals and consumers, and data analytics for outcomes research. Mr. Purcell oversaw strategic planning, clinical operations, data management, regulatory filings, and R&D and was involved with business development and out-licensing activities for the company’s technology platform.
He started his career as a molecular biologist, where he developed and patented a second generation TPA with increased half-life. He also worked at a major pharmaceutical company where he conducted primary research and published several manuscripts on the topics of AIDS and immunomodulators. Mr. Purcell also headed the Life Sciences Consulting Group for Kline and Company, where he conducted market, technology and business analysis for the commercial development of pharmaceutical and biotechnology products for therapeutic and diagnostic applications.
Rich graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is a member of NJTC, HIMSS, the Patient-Centered Primary Care Collaborative, the Drug Information Association and the Licensing Executives Society. He is also an Adjunct Professor of Biology at Monmouth University where he developed and teaches The Business of Biotechnology.
Dick Suedkamp - Executive Vice President, Finance and Accounting
Dick Suedkamp is the EVP of Finance at Nugenerex, where he manages the company's finance and accounting functions. Prior to Nugenerex, Dick spent two years in finance and accounting leadership roles at Veneto Holdings and most recently served as Chief Financial Officer. During his tenure, Dick was instrumental in building out the finance and accounting business support capabilities and function at Veneto. Dick also spent almost 12 years in public accounting in the Big 4. He received his bachelor of business administration and master of professional accounting degrees from the University of Texas at Austin and is licensed as a CPA in the state of Texas.
Steve Worster - Chief Compliance Officer
Mr. Worster has more than fifteen years of healthcare compliance experience including holding executive level positions with Cardinal Health and HMS. As part of his prior compliance rolls Mr. Worster has also been responsible for managing data security, physical security and business continuity programs. In addition to leading the compliance function, Mr. Worster will also act as the company’s Chief Privacy Officer. Prior to working in Compliance, Mr. Worster worked as a police officer for six years in suburban Columbus, Ohio and is a Veteran of the Air Force. He earned BA from The Ohio State University and his Juris Doctorate from Villanova University’s Charles Widger School of Law.
Brad Guy - Chief Human Resource Officer
Mr. Guy brings deep domain knowledge and experience in the areas of HR Strategy, Compensation and Benefits, Recruitment & Selection and Organization Design. He was previously the Vice President of Human Resources at Veneto Holdings, LLC before joining Generex as our Chief Human Resources Officer. Mr. Guy brings a wealth of experience in Healthcare, Financial Services, Strategy Consulting and Consumer Products having worked for publicly traded companies such as, Alcon Laboratories, a subsidiary of Novartis Pharmaceuticals, Yum! Brands, Inc., CapitalOne as well as diversified money managers like Highland Capital Management, LLC and strategy consulting firms. Mr. Guy began his career in management consulting and executive search. He earned his MBA with distinction from the University of Dallas and his BBA from the University of North Texas.
Ted's DD is spot on, We will be trading in this range till India gets going or some other OEM Breakthru.
Today's Trading looked like Shorts Covering. News Monday
GNBT - Buy One Share Of Biotech’s New Fast Rising Star And Get One Free
August 9, 2019 -- InvestorsHub NewsWire -- via BioResearchAlert
About: Generex Biotechnology Corporation (GNBT)
Share price in strong uptrend for past 10 months.
1 Share dividend for each share owned will only be paid the day after Generex Biotechnology is up-listed to Nasdaq.
Nasdaq Up-listing expected in 30 to 60 days.
Stock dividend will only be paid to float shareholders and not to management or insider shareholders.
Management has completely restructured company into powerful healthcare growth engine.
Generex A37 Immunotherapy Vaccine demonstrates high efficacy with low adverse side effects against breast cancer and believes it’s also effective against many common cancers and diseases.
Combination Phase II trial with MRK Keytruda and GNBT A37 for Breast Cancer enrolling 2019.
Upfront license payments for AE37 by Shenzhen BioScien Pharmaceuticals for Prostate Cancer in China, Taiwan, Hong Kong and Macau.
Proprietary buccal oral insulin delivery for $27 billion insulin market.
Aggressive acquisition strategy of diagnostics, therapeutics, orthopedic surgical implants and patient care in play with recent closes and signed LOI’s.
Summary
Shares of Generex Biotechnology Corporation (OTC: OTCQB:GNBT) have been rising and continue in a strong uptrend for several reasons. Unlike many biotech companies that are developing just one technology and have only one drug or very few drugs in their pipeline, Generex is successfully executing an aggressive acquisition strategy to own a broad spectrum of diagnostic products, therapeutic products, orthopedic implants, surgical kits, biologic products, and care delivery solutions through their MSO.
Joseph Moscoto, CEO, has thoroughly restructured Generex Biotechnology and has assembled an experienced and effective management team that has successfully architected several acquisitions that have either been closed, or that are under LOI. Each individual acquisition has the potential to generate blockbuster revenues, and each new company is either already in commercial stages or is developing attractive solutions for the $400 billion biotechnology market and the $4 trillion healthcare market.
Biotech companies are known for wild share price swings on drug development news and can see their shares either rocket on good news or crash on bad news. Biotech valuations tend to be substantially higher than most industries because the leverage of one single drug can create several billions of dollars in new wealth. A37 is a broad-spectrum, Immunotherapy drug of great interest because it has the potential to deliver therapeutic solutions for so many cancers and disease conditions. If successful, its value can be enormous. The demonstrated efficacy against breast cancer and the belief it works against a host of cancers and illnesses with minimal adverse side effects has motivated the drug giant, Merck to enter into a clinical trial with Generex.
MRK is conducting a Combination Trial for breast cancer with Generex A37 and their giant blockbuster PD1 Checkpoint Inhibitor Keytruda. As A37 moves forward with MRK, dramatically higher share prices appear to be in Generex future if positive outcomes are published. Generex current market cap of well under $200 million is very small by industry standards and subject to very large overnight revaluations on expected news runway.
Additionally, Generex has the potential to deliver large and fast-growing revenues from the several products and services currently offered and about to be offered. Further increases in Generex share valuations are likely and expected as the company begins enrollment for their combination trial and as the company gets closer to reporting revenues from several profit centers.
In the I-Box
RSI 22 == Oversold/Nearing Book Value
If Notes become "Free Trading Shares" as you state. The Note Participants are not obligated to sell and oh yes it also cleans up the balance sheet. "Death Spiral" Really
Lets say you are correct on Notes, Generex is eliminating debt and their balance sheet is improving. Also their acquisitions may benefit the balance sheet long term.
1:1 Dividend Shares & Little Dilution to make the Dividend happen. Very Nice.
I doubt that after the recent gains.
No Debt, Revenue, Oversold Probably.
Thats my point
Contact Donohoe they may provide more info than the NASDAQ.
The QDSC is the whole make or break, QMC at least has India's backing for Financing and Production. It's a wait and see game as you clearly point out in your post regarding if the efficiency numbers pan out. Nice DD Ted :)
Agreed, unplugging the share machine coming very soon
Notes are NOT Death Spirals, In QMC's case its a Bridge to Production. Notes can be paid back in cash, shares or renegotiated.
A Note is similar to a loan that can be paid in cash, shares or renegotiated. A Note does NOT equal a "Death Spiral".
More Good Info Ted Thanks